Product Summary

Cat. No.
CSI 001-71
Specificity
CSI 001-71 is highly specific for perlecan. There is no evidence for cross-reactivity with other connective tissue proteins (vitronectin, fibronectin, elastin, collagen, laminin).
Immunogen
Bovine corneal endothelial cells
Host
Mouse
Positive Species Reactivity
Bovine, Human
Negative Species Reactivity
Not determined
Isotype
IgG1/k
Gene ID
444872, 3339
Clone Number
A71
Epitope Specificity
Epitope is located in domain I
Unit Size
400 µL: Cat. No. CSI 001-71-04 1 mL: Cat. No. CSI 001-71-1 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Purification
Protein A/G purified (from culture supernatant)
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Conjugation
Unconjugated BSA free
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target
Perlecan is an extracellular matrix proteoglycan. It has a large core protein of 400-450 kDa and is often produced with heparan sulfate side chains. Perlecan is found in basement membranes where it contributes to the permeability characteristics, serves as a substrate for vascular cells and binds growth factors involved in vascular remodelling.

Application

ELISA: CSI 001-71 can be used in ELISA.

WB: In Western blotting a dilution guideline of 1/100 has proved successful. (1,2)

IHC-F: CSI 001-71 can be used in immunostaining of frozen PLP-fixed sections of bovine and human tissues.

IHC-P: CSI 001-71 can be used in immunostaining of frozen PLP-fixed sections of bovine and human tissues.

AP: CSI 001-71 can be used in affinity chromatography to separate recombinant domain I from tissue culture fluid. (1)

IP: CSI 001-71 can be used in immunoprecipitation.

Scientific References

1. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996) The degradation of human endothelial cell-derived perlecan, and release of bound bFGF by stromelysin, plasmin and heparanases. J Biol Chem 271:10079-10086.

2. Muthusamy, A, Cooper, CR, Gomes, RR JR. (2010) Soluble perlecan domain i enhances vacular endothelial growth factor-165 actibity and receptor phosphorylation in human bone marrow endothelial cells, BMC Biochem 11:43. doi: 10.1186/1471-2091-11-43.

Cat. No.
CSI 001-71
Specificity
CSI 001-71 is highly specific for perlecan. There is no evidence for cross-reactivity with other connective tissue proteins (vitronectin, fibronectin, elastin, collagen, laminin).
Immunogen
Bovine corneal endothelial cells
Host
Mouse
Positive Species Reactivity
Bovine, Human
Negative Species Reactivity
Not determined
Isotype
IgG1/k
Gene ID
444872, 3339
Clone Number
A71
Epitope Specificity
Epitope is located in domain I
Unit Size
400 µL: Cat. No. CSI 001-71-04 1 mL: Cat. No. CSI 001-71-1 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Purification
Protein A/G purified (from culture supernatant)
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Conjugation
Unconjugated BSA free
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target
Perlecan is an extracellular matrix proteoglycan. It has a large core protein of 400-450 kDa and is often produced with heparan sulfate side chains. Perlecan is found in basement membranes where it contributes to the permeability characteristics, serves as a substrate for vascular cells and binds growth factors involved in vascular remodelling.

ELISA: CSI 001-71 can be used in ELISA.

WB: In Western blotting a dilution guideline of 1/100 has proved successful. (1,2)

IHC-F: CSI 001-71 can be used in immunostaining of frozen PLP-fixed sections of bovine and human tissues.

IHC-P: CSI 001-71 can be used in immunostaining of frozen PLP-fixed sections of bovine and human tissues.

AP: CSI 001-71 can be used in affinity chromatography to separate recombinant domain I from tissue culture fluid. (1)

IP: CSI 001-71 can be used in immunoprecipitation.

1. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996) The degradation of human endothelial cell-derived perlecan, and release of bound bFGF by stromelysin, plasmin and heparanases. J Biol Chem 271:10079-10086.

2. Muthusamy, A, Cooper, CR, Gomes, RR JR. (2010) Soluble perlecan domain i enhances vacular endothelial growth factor-165 actibity and receptor phosphorylation in human bone marrow endothelial cells, BMC Biochem 11:43. doi: 10.1186/1471-2091-11-43.

×